Awaiting development: Guidance and quality standards

Skip to filters Skip to results

Showing 71 to 80 of 284

Type: GuidanceRemove Type: Guidance filter
Guidance programme: Technology appraisal guidanceRemove Guidance programme: Technology appraisal guidance filter

Guidance and quality standards awaiting development
Title	Type
Durvalumab (Imfinzi) +/- bevacizumab (Avastin) for hepatocellular carcinoma [TSID10736]	Technology appraisal guidance
Durvalumab for adjuvant treatment of hepatocellular carcinoma at high risk of recurrence after curative liver resection or ablation [ID6206]	Technology appraisal guidance
Durvalumab in combination for untreated advanced ovarian, fallopian tube or primary peritoneal cancer before and after surgery [ID6254]	Technology appraisal guidance
Durvalumab with BCG for treating high-risk non-muscle-invasive bladder cancer after resection of papillary tumours in people previously untreated with BCG [ID5080]	Technology appraisal guidance
Durvalumab with bevacizumab and transarterial chemoembolisation for treating locally advanced hepatocellular carcinoma [ID3944]	Technology appraisal guidance
Durvalumab with bevacizumab for adjuvant treatment of resected or ablated hepatocellular carcinoma at high risk of recurrence [ID6146]	Technology appraisal guidance
Durvalumab with enfortumab vedotin for neoadjuvant and adjuvant treatment of muscle-invasive bladder cancer when cisplatin is unsuitable [ID6445]	Technology appraisal guidance
Durvalumab with oleclumab or monalizumab for treating unresectable locally advanced non-small-cell lung cancer after platinum-based chemoradiotherapy [ID6626]	Technology appraisal guidance
Durvalumab with or without bevacizumab for adjuvant treatment of resected or ablated hepatocellular carcinoma at high risk of recurrence [ID6428]	Technology appraisal guidance
Durvalumab with radiotherapy for treating unresected node-negative stage 1 or 2 non-small-cell lung cancer [ID6567]	Technology appraisal guidance

Results per page

10
25
50
All